Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
KUNLUN ENERGY
00135
HK Stock MarketDetailed Quotes
WUXI BIO (02269)
- 35.900
- +0.360+1.01%
Market Closed Apr 10 16:07 CST
148.55BMarket Cap27.34P/E (TTM)
36.540High35.540Low19.41MVolume35.540Open35.540Prev Close701.82MTurnover0.47%Turnover Ratio27.34P/E (Static)4.14BShares44.00052wk High2.84P/B148.55BFloat Cap19.82052wk Low--Dividend TTM4.14BShs Float148.000Historical High--Dividend LFY2.81%Range %8.333Historical Low36.149Avg Price500Lot Size--Div Yield TTM--Div Yield LFY
WUXI BIO (02269) Income Statement
All
YOY
| (FY)Dec 31, 2025 | (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 16.68%21.79B | 16.08%9.95B | 9.63%18.68B | 0.97%8.57B | 11.56%17.03B | 17.84%8.49B | 48.38%15.27B | 63.53%7.21B | 83.35%10.29B | 126.67%4.41B |
| Operating income | 16.68%21.79B | 16.08%9.95B | 9.63%18.68B | 0.97%8.57B | 11.56%17.03B | 17.84%8.49B | 48.38%15.27B | 63.53%7.21B | 83.35%10.29B | 126.67%4.41B |
| Cost of sales | -6.78%-11.77B | -9.11%-5.7B | -8.02%-11.02B | -5.94%-5.22B | -19.45%-10.21B | -30.01%-4.93B | -56.46%-8.54B | -79.78%-3.79B | -77.34%-5.46B | -82.39%-2.11B |
| Operating expenses | -6.78%-11.77B | -9.11%-5.7B | -8.02%-11.02B | -5.94%-5.22B | -19.45%-10.21B | -30.01%-4.93B | -56.46%-8.54B | -79.78%-3.79B | -77.34%-5.46B | -82.39%-2.11B |
| Gross profit | 30.95%10.02B | 26.95%4.25B | 12.05%7.65B | -5.92%3.35B | 1.55%6.83B | 4.32%3.56B | 39.25%6.72B | 48.60%3.41B | 90.64%4.83B | 191.73%2.3B |
| Selling expenses | -28.55%-608.82M | -21.09%-270.11M | -61.08%-473.6M | -111.65%-223.06M | -80.47%-294.01M | -57.06%-105.39M | -30.70%-162.91M | -11.18%-67.1M | -32.02%-124.65M | -24.55%-60.36M |
| Administrative expenses | -1.85%-1.7B | -1.05%-781.13M | -11.91%-1.67B | -13.73%-772.99M | -17.78%-1.5B | -30.67%-679.64M | -44.94%-1.27B | -49.61%-520.11M | -71.27%-875.93M | -70.93%-347.64M |
| Research and development expenses | -11.34%-853.37M | 0.16%-343.51M | 2.47%-766.44M | -0.77%-344.06M | -15.09%-785.82M | -25.93%-341.44M | -36.13%-682.82M | -135.00%-271.13M | -65.14%-501.58M | 7.27%-115.38M |
| Impairment and provision | -35.28%-205.33M | 29.62%-133.84M | 52.56%-151.78M | -44.29%-190.17M | -23.77%-319.97M | -86.05%-131.8M | -65.02%-258.53M | 46.80%-70.84M | -29.41%-156.67M | -135.33%-133.17M |
| -Other impairment is provision | -35.28%-205.33M | 29.62%-133.84M | 52.56%-151.78M | -44.29%-190.17M | -23.77%-319.97M | -86.05%-131.8M | -65.02%-258.53M | 46.80%-70.84M | -29.41%-156.67M | -135.33%-133.17M |
| Special items of operating profit | 85.35%753.47M | 167.70%687.39M | 1.74%406.5M | -15.93%256.78M | -62.73%399.54M | -34.84%305.43M | 24.33%1.07B | 6.83%468.77M | 71.24%862.24M | 17.28%438.81M |
| Operating profit | 48.24%7.4B | 64.30%3.41B | 15.23%4.99B | -20.38%2.08B | -20.10%4.33B | -11.68%2.61B | 34.47%5.42B | 42.02%2.95B | 101.03%4.03B | 185.35%2.08B |
| Financing cost | 9.22%-143.06M | -22.72%-83.54M | 0.57%-157.59M | 13.63%-68.07M | -146.17%-158.49M | -247.82%-78.82M | -64.28%-64.38M | -8.56%-22.66M | 8.29%-39.19M | 6.83%-20.87M |
| Earning before tax | 50.11%7.26B | 65.71%3.33B | 15.83%4.83B | -20.59%2.01B | -22.10%4.17B | -13.69%2.53B | 34.18%5.36B | 42.36%2.93B | 103.13%3.99B | 191.90%2.06B |
| Tax | -71.39%-1.52B | -150.58%-571.49M | -47.39%-889.03M | -19.33%-228.07M | 25.34%-603.18M | 38.13%-191.12M | -66.73%-807.87M | -76.07%-308.91M | -77.44%-484.54M | -785.41%-175.45M |
| After-tax profit from continuing operations | 45.32%5.73B | 54.84%2.76B | 10.50%3.95B | -23.85%1.78B | -21.52%3.57B | -10.81%2.34B | 29.68%4.55B | 39.22%2.62B | 107.28%3.51B | 157.67%1.88B |
| Earning after tax | 45.32%5.73B | 54.84%2.76B | 10.50%3.95B | -23.85%1.78B | -21.52%3.57B | -10.81%2.34B | 29.68%4.55B | 39.22%2.62B | 107.28%3.51B | 157.67%1.88B |
| Minority profit | 39.98%824.88M | 48.40%417.35M | 244.83%589.29M | 295.07%281.23M | 31.84%170.9M | -17.38%71.19M | 7.92%129.62M | 112.02%86.16M | 3,053.97%120.1M | 851.30%40.64M |
| Profit attributable to shareholders | 46.25%4.91B | 56.05%2.34B | -1.28%3.36B | -33.86%1.5B | -23.09%3.4B | -10.59%2.27B | 30.45%4.42B | 37.62%2.54B | 100.63%3.39B | 150.25%1.84B |
| Basic earnings per share | 48.78%1.22 | 56.76%0.58 | 0.00%0.82 | -32.73%0.37 | -22.64%0.82 | -9.84%0.55 | 30.86%1.06 | 38.64%0.61 | 88.37%0.81 | 131.58%0.44 |
| Diluted earnings per share | 48.72%1.16 | 57.14%0.55 | 1.30%0.78 | -32.69%0.35 | -23.76%0.77 | -10.34%0.52 | 31.17%1.01 | 38.10%0.58 | 92.50%0.77 | 133.33%0.42 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
| Auditor | -- | -- | Deloitte Touche Tohmatsu CPA LLP | -- | Deloitte Touche Tohmatsu CPA LLP | -- | Deloitte Touche Tohmatsu CPA LLP | -- | Deloitte Touche Tohmatsu CPA LLP | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome
牛牛課堂
Oct 13, 2025 18:05
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
Food流油
Apr 14, 2025 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"